Advances and Considerations in the Management of Actinic Keratosis: An Expert Consensus Panel Report

August 2021 | Volume 20 | Issue 8 | Original Article | 888 | Copyright © August 2021


Published online July 30, 2021

James Del Rosso DO (Panel Chair),a April W. Armstrong MD MPH,b Brian Berman MD PhD,c Neal Bhatia MD,d Clay Cockerell MD MBA,e Gary Goldenberg MD,f Joslyn Kirby MD MS MEd,g Mark Lebwohl MD,h Linda Stein Gold MD,i Justin W. Marson MD,j Darrell S. Rigel MD MSk

aResearch Director/Clinical Dermatology, JDR Dermatology Research/Thomas Dermatology, Las Vegas, NV
bDepartment of Dermatology, Keck School of Medicine University of Southern California, Los Angeles, CA
cDepartment of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL
dDirector of Clinical Dermatology, Therapeutics Clinical Research, San Diego, CA
eDepartment of Dermatopathology, University of Texas Southwestern Medical Center, Dallas, TX
fGoldenberg Dermatology; Icahn School of Medicine at Mount Sinai, Department of Dermatology, New York, NY
gDepartment of Dermatology, Penn State Milton S Hershey Medical Center, Hershey, PA
hDepartment of Dermatology, Icahn School of Medicine, Mount Sinai, New York, NY
iDepartment of Dermatology, Henry Ford Medical Center, Detroit, MI
jNational Society for Cutaneous Medicine, New York, NY
kDepartment of Dermatology, NYU Grossman School of Medicine, New York, NY

37. Tanaka N, Ohata C, Ishii N, Imamura K, Ueda A, Furumura M, Yasumoto S, Kawakami T, Tsuruta D, Hashimoto T. Comparative study for the effect of photodynamic therapy, imiquimod immunotherapy and combination of both therapies on 40 lesions of actinic keratosis in Japanese patients. J Dermatol. 2013 Dec;40(12):962-7. doi: 10.1111/1346-8138.12310. Epub 2013 Oct 22. PMID: 24147543.
38. Cunningham TJ, Tabacchi M, Eliane JP, Tuchayi SM, Manivasagam S, Mirzaalian H, Turkoz A, Kopan R, Schaffer A, Saavedra AP, Wallendorf M, Cornelius LA, Demehri S, “Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy,” J Clin Invest. 2017 Jan 3;127(1):106-116. doi: 10.1172/JCI89820. Epub 2016 Nov 21
39. Stockfleth E, Peris K, Guillen C, Cerio R, Basset-Seguin N, Foley P, Sanches J, Culshaw A, Erntoft S, Lebwohl M. A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosis. Int J Dermatol. 2015;54(5):509-15. doi: 10.1111/ijd.12840. Epub 2015 Apr 10. PMID: 25865875; PMCID: PMC4437053.
40. Shergill B, Zokaie S, Carr AJ. Non-adherence to topical treatments for actinic keratosis. Patient Prefer Adherence. 2013 Dec 17;8:3541. doi: 10.2147/PPA. S47126. PMID: 24379656; PMCID: PMC3872140.
41. Cerio R. The importance of patient-centred care to overcome barriers in the management of actinic keratosis. J Eur Acad Dermatol Venereol. 2017 Mar;31 Suppl 2:17-20. doi: 10.1111/jdv.14091. PMID: 28263022.
42. Chinnasamy, S, Zameer, F, Muthuchelian, K. Molecular and biological mechanisms of apoptosis and its detection techniques. J Oncol Sci. 2020;6(1):49-64. Doi: 10.37047/jos.2020-73477
43. Gupta AK, Paquet M. Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. Br J Dermatol. 2013 Aug;169(2):250-9. doi: 10.1111/bjd.12343. PMID: 23550994.
44. Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol. 2012 Mar;66(3):486-93. doi: 10.1016/j.jaad.2010.12.038. Epub 2011 Nov 4. PMID: 22055282.
45. Solaraze 3% Gel. Package Insert. Amirall, LLC. 2021
46. Blauvelt A, Kempers S, Forman S, Lain E, Bruce S. Tirbanibulin ointment 1%, a novel inhibitor of tubulin polymerization and Src kinase signaling, for the treatment of actinic keratosis (AK): Results from two pivotal phase III studies. SKIN The Journal of Cutaneous Medicine. 2020;4(5):s63. https://doi. org/10.25251/skin.4.supp.62
47. Blauvelt A, Kempers S, Schlesinger T, Lain E, Wang H, Cutler D, Lebwohl M, Fang J, Kwan R. Tirbanibulin ointment 1% for actinic keratosis (AK): Pooled data from two phase 3 studies. SKIN The Journal of Cutaneous Medicine. 2020;4(6):s121. https://doi.org/10.25251/skin.4.supp.121
48. Blauvelt A, Kempers S, Lain E, Schlesinger T, Tyring S, Forman S, Ablon G, Martin G, Wang H, Cutler DL, Fang J, Kwan MR. Phase 3 tirbanibulin for actinic keratosis group. Phase 3 trials of tirbanibulin ointment for actinic keratosis. N Engl J Med. 2021 Feb 11;384(6):512-520. doi: 10.1056/ NEJMoa2024040. PMID: 33567191.
49. Bubna AK. Imiquimod - Its role in the treatment of cutaneous malignancies. Indian J Pharmacol. 2015;47(4):354-359. doi:10.4103/0253-7613.16124
50. Smolinski MP, Bu Y, Clements J, Gelman IH, Hegab T, Cutler DL, Fang JWS, Fetterly G, Kwan R, Barnett A, Lau JYN, Hangauer DG. Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361). Journal of Medicinal Chemistry. 2018;61:4704– 4719.. doi:10.1021/acs.jmedchem.8b00164
51. Marson, JW, Del Rosso, J, Bhatia, N, Rigel, DS. (2021). Considerations in the Management of Actinic Keratoses: The Importance of Adherence and Persistence to Therapy. SKIN The Journal of Cutaneous Medicine. 5(2), 83-88 https://doi.org/10.25251/skin.5.2.1
52. Freeman S, Bettencourt M, Corliss M, Dunkelly-Allen N, Veverka KA. Evaluation of Different Approaches in Managing Local Skin Reactions With the Use of Ingenol Mebutate 0.015% and 0.05% During the Treatment of Actinic Keratosis. SKIN The Journal of Cutaneous Medicine. 2020;4(5):s65. https://doi.org/10.25251/skin.4.supp.64

AUTHOR CORRESPONDENCE

Justin W. Marson MD justin.w.marson@gmail.com
Close Menu